AnaptysBio, Inc. (ANAB)
54.15
-0.76
(-1.38%)
USD |
NASDAQ |
Jul 24, 16:00
53.97
-0.18
(-0.33%)
After-Hours: 20:00
AnaptysBio EPS Diluted (Quarterly) : -1.843 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -1.843 |
| December 31, 2025 | 1.583 |
| September 30, 2025 | 0.5208 |
| June 30, 2025 | -1.341 |
| March 31, 2025 | -1.283 |
| December 31, 2024 | -0.7154 |
| September 30, 2024 | -1.137 |
| June 30, 2024 | -1.706 |
| March 31, 2024 | -1.639 |
| December 31, 2023 | -1.588 |
| September 30, 2023 | -1.405 |
| June 30, 2023 | -1.496 |
| March 31, 2023 | -1.583 |
| December 31, 2022 | -0.9285 |
| September 30, 2022 | -1.184 |
| June 30, 2022 | -1.154 |
| March 31, 2022 | -1.308 |
| December 31, 2021 | -1.182 |
| September 30, 2021 | -0.243 |
| June 30, 2021 | -0.0157 |
| March 31, 2021 | -0.6638 |
| December 31, 2020 | 1.204 |
| September 30, 2020 | -0.8701 |
| June 30, 2020 | -0.7899 |
| March 31, 2020 | -0.303 |
| Date | Value |
|---|---|
| December 31, 2019 | -0.7462 |
| September 30, 2019 | -1.147 |
| June 30, 2019 | -0.8866 |
| March 31, 2019 | -0.8183 |
| December 31, 2018 | -0.6344 |
| September 30, 2018 | -0.6609 |
| June 30, 2018 | -0.569 |
| March 31, 2018 | -0.6338 |
| December 31, 2017 | -0.2972 |
| September 30, 2017 | -0.446 |
| June 30, 2017 | -0.1324 |
| March 31, 2017 | -0.7476 |
| December 31, 2016 | -0.2139 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.0446 |
| March 31, 2016 | -0.05 |
| December 31, 2015 | -0.1764 |
| September 30, 2015 | -0.0734 |
| June 30, 2015 | -0.0028 |
| March 31, 2015 | -0.0189 |
| December 31, 2014 | -0.0029 |
| September 30, 2014 | 0.036 |
| June 30, 2014 | 0.0384 |
| March 31, 2014 | -0.0599 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Agenus, Inc. | 1.023 |
| Precision BioSciences, Inc. | -0.7486 |
| 4D Molecular Therapeutics, Inc. | -1.010 |
| Design Therapeutics, Inc. | -0.2871 |
| Inhibrx Biosciences, Inc. | -2.146 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -52.88M |
| Revenue (Quarterly) | 25.56M |
| Total Expenses (Quarterly) | 78.44M |
| Enterprise Value | 1.563B |
| Gross Profit Margin (Quarterly) | 97.61% |
| Profit Margin (Quarterly) | -206.9% |
| Earnings Yield | -2.00% |
| Operating Earnings Yield | 2.56% |
| Normalized Earnings Yield | -1.995 |